Danaher Corporation (DAP.F)
| Previous Close | 235.20 |
| Open | 235.75 |
| Bid | 233.50 x 60000 |
| Ask | 233.70 x 60000 |
| Day's Range | 234.00 - 235.75 |
| 52 Week Range | 172.30 - 238.15 |
| Volume | |
| Avg. Volume | 440 |
| Market Cap | 173.321B |
| Beta (5Y Monthly) | 0.85 |
| PE Ratio (TTM) | 46.25 |
| EPS (TTM) | 5.06 |
| Earnings Date | Jul 23, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | 1.00 (0.43%) |
| Ex-Dividend Date | Jun 28, 2024 |
| 1y Target Est | 331.45 |
The TelegraphQuestor: This biotech giant is backed by the world’s best fund managers
Remember Abcam? The Cambridge-based biotech was a darling of the Aim market until it decided in late-2022 to abandon London in favour of a listing on the US exchange Nasdaq.
PR NewswireDanaher Launches Collaboration with Johns Hopkins University Aiming to Improve Neurological Diagnosis
Danaher Corporation (NYSE: DHR), a global science and technology innovator ("Danaher"), today launched a collaboration with Johns Hopkins University aiming to develop new methods for diagnosing mild TBI. As part of the Danaher Beacons program, researchers at Johns Hopkins University will leverage technology from Beckman Coulter Diagnostics, a Danaher subsidiary and leader in clinical diagnostics, to potentially establish correlations between a new biomarker panel and clinical outcomes.
ZacksDanaher Corporation (DHR) Is a Trending Stock: Facts to Know Before Betting on It
Danaher (DHR) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
